Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryWhat made the headlines this summer: the top stories you might have missedLegal Business7 Sep 2026In numbers: How Slaughters’ £110m fee haul doubles nearest rival on UK’s biggest dealsLaw firmsKate Peacock3 Sep 2026Revolving Doors: latest hires for Eversheds Sutherland, HFW and Bird & BirdLaw firmsNews Editor2 Sep 2026Kirkland trio set to rejoin Latham in latest Saudi pushLaw firmsWill Lewallen8 Sep 2026Private equity heavyweight David Walker to leave Latham after 13 yearsLaw firmsWill Lewallen8 Sep 2026US firms lead as Nvidia acquires Hugging Face for $13bnLaw firmsWill Lewallen4 Sep 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025